These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30981650)

  • 1. DC-based immunotherapy as strategy to purge the HIV reservoir?
    Søgaard OS
    EBioMedicine; 2019 May; 43():16-17. PubMed ID: 30981650
    [No Abstract]   [Full Text] [Related]  

  • 2. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
    Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
    EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway.
    van Montfort T; van der Sluis R; Darcis G; Beaty D; Groen K; Pasternak AO; Pollakis G; Vink M; Westerhout EM; Hamdi M; Bakker M; van der Putten B; Jurriaans S; Prins JH; Jeeninga R; Thomas AAM; Speijer D; Berkhout B
    EBioMedicine; 2019 Apr; 42():97-108. PubMed ID: 30824386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells.
    Ruiz A; Blanch-Lombarte O; Jimenez-Moyano E; Ouchi D; Mothe B; Peña R; Galvez C; Genescà M; Martinez-Picado J; Goulder P; Barnard R; Howell B; Clotet B; Prado JG
    Front Immunol; 2018; 9():3162. PubMed ID: 30723480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill.
    Kristoff J; Rinaldo CR; Mailliard RB
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31905690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.
    Euler Z; Alter G
    AIDS Res Hum Retroviruses; 2015 Jan; 31(1):13-24. PubMed ID: 25385703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peering into the HIV reservoir.
    García M; Buzón MJ; Benito JM; Rallón N
    Rev Med Virol; 2018 Jul; 28(4):e1981. PubMed ID: 29744964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro.
    Anderson JL; Mota TM; Evans VA; Kumar N; Rezaei SD; Cheong K; Solomon A; Wightman F; Cameron PU; Lewin SR
    PLoS One; 2016; 11(7):e0158778. PubMed ID: 27383184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir.
    Liu B; Zhang W; Zhang H
    Curr Opin Virol; 2019 Oct; 38():21-30. PubMed ID: 31132749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges and strategies for the eradication of the HIV reservoir.
    Kimata JT; Rice AP; Wang J
    Curr Opin Immunol; 2016 Oct; 42():65-70. PubMed ID: 27288651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Antiviral Immune Response and Its Impact on the HIV-1 Reservoir.
    Veenhuis RT; Blankson JN
    Curr Top Microbiol Immunol; 2018; 417():43-67. PubMed ID: 29071476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4
    Agosto LM; Henderson AJ
    AIDS Res Hum Retroviruses; 2018 Sep; 34(9):780-789. PubMed ID: 29869531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents.
    Vollbrecht T; Angerstein AO; Menke B; Kumar NM; de Oliveira MF; Richman DD; Guatelli JC
    Retrovirology; 2020 Nov; 17(1):36. PubMed ID: 33228686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A division of labor: DC subsets and HIV receptor diversity.
    Kavanagh DG; Bhardwaj N
    Nat Immunol; 2002 Oct; 3(10):891-3. PubMed ID: 12352961
    [No Abstract]   [Full Text] [Related]  

  • 16. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
    Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
    J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses.
    Ostrowski MA; Justement SJ; Ehler L; Mizell SB; Lui S; Mican J; Walker BD; Thomas EK; Seder R; Fauci AS
    J Immunol; 2000 Dec; 165(11):6133-41. PubMed ID: 11086046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4
    Kumar NA; van der Sluis RM; Mota T; Pascoe R; Evans VA; Lewin SR; Cameron PU
    J Immunol; 2018 Sep; 201(5):1468-1477. PubMed ID: 30030324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.